Beinse, Guillaume
Just, Pierre-Alexandre
Le Frere Belda, Marie-Aude
Laurent-Puig, Pierre http://orcid.org/0000-0001-8475-5459
Jacques, Sebastien
Koual, Meriem
Garinet, Simon http://orcid.org/0000-0002-2182-8793
Leroy, Karen http://orcid.org/0000-0002-4379-0140
Delanoy, Nicolas
Blons, Helene
Gervais, Claire
Durdux, Catherine
Chapron, Charles
Goldwasser, François
Terris, Benoit
Badoual, Cecile
Taly, Valerie http://orcid.org/0000-0002-3116-8602
Bats, Anne-Sophie
Borghese, Bruno
Alexandre, Jérôme http://orcid.org/0000-0001-5252-5800
Article History
Received: 1 March 2022
Revised: 3 June 2022
Accepted: 15 June 2022
First Online: 25 June 2022
Competing interests
: GB: institutional funding from ITMO Cancer AVIESAN (French National Cancer Institute); JA: research funding from MSD; advisory board: GSK, MSD, AstraZeneca, Clovis, Eisaï. No external entities had any role in the design and conduction of the study, the collection, management, analysis, and interpretation of the data, the preparation, review and approval of the manuscript or the decision to submit the manuscript for publication. The remaining authors declare no competing interests.
: Patients treated for Stage I–IV UCEC in two University Hospitals in Paris [2010–2017] were post hoc included and referred as to the CAncer Research for Personalised Medicine Institute upon written consent or non-opposition (CARPEM) cohort (ethical approvals from National Ethical Committee CPP Ile-de-France I II & IV, DC-2020/144; DC-2019-3677; DC-2009-950, Data Protection Committee approval ID APHP2020-1109121347).
: Not applicable.